Vertex Pharmaceuticals Incorporated (BMV:VRTX)

Market Cap	2.07T
Revenue (ttm)	215.03B
Net Income (ttm)	67.41B
Shares Out	n/a
EPS (ttm)	260.87
PE Ratio	30.72
Forward PE	22.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218
Average Volume	236
Open	8,217.34
Previous Close	n/a
Day's Range	8,217.34 - 8,242.96
52-Week Range	6,800.00 - 10,318.00
Beta	0.32
RSI	59.15
Earnings Date	Feb 2, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: VRTX

Financial Performance

Financial numbers in USD